Checkpoint Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Additional Information (Details)

Stockholders' Equity - Additional Information (Details) $ / shares in Units, $ in Thousands		1 Months Ended				3 Months Ended		6 Months Ended
	Jan. 01, 2023 shares	Jul. 31, 2023 USD ($) $ / shares shares	May 31, 2023 USD ($) $ / shares shares	Apr. 30, 2023 USD ($) $ / shares shares	Feb. 28, 2023 USD ($) $ / shares shares	Jun. 30, 2023 USD ($) Vote multiplier $ / shares shares	Jun. 30, 2022 USD ($)	Jun. 30, 2023 USD ($) Vote multiplier $ / shares shares	Jun. 30, 2022 USD ($)	Jun. 12, 2023 $ / shares shares	Mar. 31, 2023 USD ($)	Dec. 31, 2022 $ / shares shares	Nov. 03, 2022 Vote shares	Nov. 30, 2020 USD ($)	Mar. 17, 2015
Stockholders' Equity
Common stock, increase in the number of authorized shares (in shares)										30,000,000
Common stock, shares authorized						80,000,000		80,000,000		80,000,000		50,000,000
Common stock, par value (in dollars per share) \| $ / shares						$ 0.0001		$ 0.0001		$ 0.0001		$ 0.0001
Common stock, shares outstanding						17,238,393		17,238,393				9,586,683
Number of votes per share \| Vote						1		1
Multiplier to calculate voting rights per class A common share						1.1		1.1					13.5
Number of non assessable shares issued upon conversion						1		1
Shelf registration statement, maximum authorized securities \| $														$ 100,000
Issuance of common shares - Founders agreement \| $						$ 402	$ 17	$ 558	$ 213
Equity Method Investment, Annual Equity Fee, Percentage															2.50%
Non-vested restricted stock
Stockholders' Equity
Total unrecognized compensation cost related to non-vested \| $						$ 3,600		$ 3,600
Weighted average period (in years)								2 years 1 month 6 days
Performance Shares
Stockholders' Equity
Restricted stock outstanding non-vested						196,733		196,733
2015 Incentive Plan
Stockholders' Equity
Number of shares available for issuance authorized						6,000,000		6,000,000
Plans expires (in years)								10 years
Shares are available for issuance						3,496,830		3,496,830
Maximum \| 2015 Incentive Plan
Stockholders' Equity
Number of shares available for issuance authorized													3,000,000
Minimum \| 2015 Incentive Plan
Stockholders' Equity
Number of shares available for issuance authorized													900,000
At the market offering (ATM)
Stockholders' Equity
Percentage of annual equity fee	2.50%
Number of shares issued and sold	368,907
Gross proceeds \| $									8,910
Amount of commissions and other transaction costs \| $									$ 223
February 2023 Registered Direct Offering
Stockholders' Equity
Purchase price per share \| $ / shares					$ 5.25
Number of shares issued and sold					1,180,000
Number of warrants issued					248,572
Gross proceeds \| $					$ 7,500
Net proceeds from offering \| $					6,700
Amount of commissions and other transaction costs \| $					$ 800
February 2023 Registered Direct Offering \| Pre-Funded Warrants
Stockholders' Equity
Number of warrants issued					248,572
Price of warrant \| $ / shares					$ 5.2499
February 2023 Registered Direct Offering \| Series A warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares					1,428,572
Price of warrant \| $ / shares					$ 5.00
Expiration term of warrants (in years)					5 years
February 2023 Registered Direct Offering \| Series B warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares					1,428,572
Price of warrant \| $ / shares					$ 5.00
Expiration term of warrants (in years)					18 months
February 2023 Registered Direct Offering \| Maximum \| Series A warrants
Stockholders' Equity
Number of shares issued and sold					1,428,572
February 2023 Registered Direct Offering \| Maximum \| Series B warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares					1,428,572
April 2023 Direct Offering
Stockholders' Equity
Purchase price per share \| $ / shares				$ 3.60
Commissions and other transaction costs \| $				$ 600
Shelf registration statement remaining authorized securities \| $						$ 8,700		$ 8,700			$ 150,000
Number of shares issued and sold				1,700,000
Gross proceeds \| $				$ 6,100
Net proceeds from offering \| $				5,500
Amount of commissions and other transaction costs \| $				$ 600
April 2023 Direct Offering \| Series A warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares				1,700,000
Price of warrant \| $ / shares				$ 3.35
Expiration term of warrants (in years)				5 years
April 2023 Direct Offering \| Series B warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares				1,700,000
Price of warrant \| $ / shares				$ 3.35
Expiration term of warrants (in years)				18 months
April 2023 Direct Offering \| Maximum \| Series A warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares				1,700,000
April 2023 Direct Offering \| Maximum \| Series B warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares				1,700,000
May 2023 Registered Direct Offering
Stockholders' Equity
Purchase price per share \| $ / shares			$ 3.071
Number of shares issued and sold			1,650,000
Number of warrants issued			1,606,269
Price of warrant \| $ / shares			$ 3.0709
Gross proceeds \| $			$ 10,000
Net proceeds from offering \| $			9,100
Amount of commissions and other transaction costs \| $			$ 900
May 2023 Registered Direct Offering \| Pre-Funded Warrants
Stockholders' Equity
Number of warrants issued			1,606,269
Price of warrant \| $ / shares			$ 3.0709
Class of Warrant or Right, Exercised						459,269
May 2023 Registered Direct Offering \| Series A warrants
Stockholders' Equity
Price of warrant \| $ / shares			$ 2.821
Expiration term of warrants (in years)			5 years
May 2023 Registered Direct Offering \| Series B warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares			3,256,269
Price of warrant \| $ / shares			$ 2.821
Expiration term of warrants (in years)			18 months
May 2023 Registered Direct Offering \| Maximum \| Series A warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares			3,256,269
May 2023 Registered Direct Offering \| Maximum \| Series B warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares			3,256,269
July 2023 Registered Direct Offering \| Subsequent Event
Stockholders' Equity
Purchase price per share \| $ / shares		$ 3.09
Number of shares issued and sold		2,427,186
Gross proceeds \| $		$ 10,000
Net proceeds from offering \| $		9,100
Amount of commissions and other transaction costs \| $		$ 900
July 2023 Registered Direct Offering \| Subsequent Event \| Pre-Funded Warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares		809,062
Price of warrant \| $ / shares		$ 3.0899
July 2023 Registered Direct Offering \| Subsequent Event \| Series A warrants
Stockholders' Equity
Price of warrant \| $ / shares		$ 2.84
Expiration term of warrants (in years)		5 years
July 2023 Registered Direct Offering \| Subsequent Event \| Series B warrants
Stockholders' Equity
Price of warrant \| $ / shares		$ 2.84
Expiration term of warrants (in years)		18 months
July 2023 Registered Direct Offering \| Maximum \| Subsequent Event \| Series A warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares		3,236,248
July 2023 Registered Direct Offering \| Maximum \| Subsequent Event \| Series B warrants
Stockholders' Equity
Number of warrants issued and sold to purchase shares		3,236,248
Fortress
Stockholders' Equity
Issuance of common shares - Founders agreement \| $								600
Shelf registration statement remaining authorized securities \| $						$ 120,900		$ 120,900
Percentage of annual equity fee								2.50%
Equity Method Investment, Annual Equity Fee, Percentage	2.50%
Number of shares issued and sold	368,907							159,620
Agent
Stockholders' Equity
Commission rate														3.00%
Common Class A
Stockholders' Equity
Common stock, shares authorized										700,000
Common stock, shares outstanding						700,000		700,000				700,000